logo-loader
viewTissue Regenix Group PLC

Tissue Regenix chief executive steps down as illness recurs

John Samuel will resume as executive chairman until a full-time chief executive is appointed

knee
Tissue Regenix specialises in regenerative medicine and implants

Tissue Regenix PLC’s  (LON:TRX) chief executive Steve Cauldwell is to step down permanently after a recurrence of the illness that kept him away from January to June.

John Samuel will resume as executive chairman until a full-time chief executive is appointed while current COO Gareth Jones will become interim- CEO.

Cauldwell said: “ The company is at such an exciting point of commercial and operational inflection and I remain committed to being available as an adviser and mentor wherever possible."

Quick facts: Tissue Regenix Group PLC

Price: 0.33 GBX

AIM:TRX
Market: AIM
Market Cap: £23.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read